The evolving role of cetuximab in non-small cell lung cancer.

Clin Cancer Res

Thoracic Oncology Program, Mount Sinai Cancer Center, Miami Beach, Florida 33140, USA.

Published: July 2006

Cetuximab is a monoclonal antibody directed against the ligand binding site in the extracellular domain of the epidermal growth factor receptor (EGFR). Cetuximab is currently approved for the treatment of patients with refractory colorectal cancer. In locally advanced head and neck carcinoma, cetuximab in combination with radiotherapy significantly improved survival compared with radiotherapy alone, and this treatment awaits Food and Drug Administration approval. In previously treated non-small cell lung cancer, single-agent cetuximab produced an objective response in 3 of 66 eligible patients and a median survival of 8.1 months. Treatment was well tolerated, with skin rash as the principal toxicity. The vast majority of patients (60 of 66) expressed EGFR by immunohistochemistry but no correlation existed between response and EGFR mutations. Two single-arm phase II trials testing cetuximab in combination with a platinum-based doublet in previously untreated patients showed responses in the range of 26% to 29%, with median survival times of 10 to 11 months. A European phase II randomized trial tested cisplatin/vinorelbine with or without cetuximab as first-line therapy in 86 patients with advanced non-small-cell lung cancer. Overall efficacy was slightly superior in the cetuximab arm and a phase III trial is currently ongoing to definitively determine the role of cetuximab in this setting.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0097DOI Listing

Publication Analysis

Top Keywords

lung cancer
12
cetuximab
9
role cetuximab
8
non-small cell
8
cell lung
8
cetuximab combination
8
median survival
8
patients
5
evolving role
4
cetuximab non-small
4

Similar Publications

Patient-Centered Physical Activity Intervention in Lung Cancer Patients: A Clinical Severity and Functional Capacity Systematic Review and Meta-analysis.

Cancer Nurs

January 2025

Author Affiliations: Departments of Physiotherapy (Drs Heredia Ciuró, Martín Núñez, Navas Otero, Calvache Mateo, Torres Sánchez, and Valenza) and Nursing (Dr Granados Santiago), Faculty of Health Sciences, University of Granada, Granada, Spain.

Background: Increasing physical activity levels is a significant unmet need in cancer survivors, and it can likely be enhanced through a better understanding of the interventions developed. Some studies on patient-centered physical activity interventions have shown promising results in increasing daily activity levels among lung cancer survivors. However, the programs present a high heterogeneity, and there is no consensus on the parameters and their effectiveness.

View Article and Find Full Text PDF

NRG1 Fusions: The New Kid on the Block.

Curr Oncol Rep

January 2025

Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC, 20007, USA.

Purpose Of Review: Neuregulin 1 (NRG1) fusions are rare but actionable oncogenic drivers that occur in a variety of tumor types, including non-small cell lung cancer (NSCLC). These fusions lead to pathophysiologic activation of HER signaling pathways, promoting tumor growth, invasion, and metastasis. Current evidence suggests that NRG1 fusion-positive NSCLC does not respond well to conventional treatments such as immunotherapy and chemotherapy.

View Article and Find Full Text PDF

Minimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.

Cancer Metastasis Rev

January 2025

Saliva and Liquid Biopsy Translational Laboratory, Institute for Biomedicine and Glycomics (IBG), Griffith University, Brisbane, 4111, Australia.

CT chest scans are commonly performed worldwide, either in routine clinical practice for a wide range of indications or as part of lung cancer screening programs. Many of these scans detect lung nodules, which are small, rounded opacities measuring 8-30 mm. While the concern about nodules is that they may represent early lung cancer, in screening programs, only 1% of such nodules turn out to be cancer.

View Article and Find Full Text PDF

Patterns of lymph node metastasis and long-term outcomes of splenic flexure colon cancer: a descriptive study from a Japanese high-volume center.

Surg Today

January 2025

Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-Ku, Tokyo, 135-8550, Japan.

Purpose: The pattern of lymph node metastasis and the appropriate extent of lymph node dissection in splenic flexure colon cancer remain unclear. This study aimed to describe the clinical characteristics, lymph node metastasis patterns, and oncological outcomes of patients with splenic flexure colon cancer.

Methods: The data of patients with splenic flexure cancer diagnosed with pathological stages I-III were extracted from a hospital database.

View Article and Find Full Text PDF

Non-small cell lung cancer (NSCLC) is a widespread highly malignant type of lung cancer. Conventional chemotherapeutic drugs may be accompanied by both drug resistance and serious side effects in patients. Therefore, safer and more effective medications are urgently needed for the treatment of NSCLC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!